Pfizer has axed two clinical-stage obesity programs, dropping a GLP-1 receptor agonist from the Metsera buyout and a GIPR antagonist as part of its quarterly pipeline cleanout.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Pfizer has axed two clinical-stage obesity programs, dropping a GLP-1 receptor agonist from the Metsera buyout and a GIPR antagonist as part of its quarterly pipeline cleanout.